EXHIBIT L

I hereby certify that this paper is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 377984043 US, on the date shown below in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: May 30, 2007

Signature: Founday Tulyic Salmeron)

Patent Docket No. 543312000420

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Patent Application of:
Revinder S. DHALLAN

Serial No.: 10/661,165

Filing Date: September 11, 2003

For: METHODS FOR DETECTION OF

GENETIC DISORDERS

Examiner: E. Whisenant

Group Art Unit: 1634

Confirmation No.: 7501

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicant submits for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

This Supplemental Information Disclosure Statement is submitted:

With the application; accordingly, no fee or separate requirements are required.
Before the mailing of a first Office Action after the filing of a Request for Continued
Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97
(e)(1) has been provided.

36/01/2007 WABBELR1 00000050 031952

Applic	cation S	erial No. 10/661,165 Patent
	Withir	Docket No. 543312000420 three months of the application filing date or before mailing of a first Office Action
	on the	merits; accordingly, no fee or separate requirements are required. However, if
	applica	able, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
\boxtimes	After 1	receipt of a first Office Action on the merits but before mailing of a final Office Action
	or Not	ice of Allowance.
		A fee is required. A check in the amount of is enclosed.
	\boxtimes	A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to
		this submission in duplicate.
		A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is
		believed to be due.
	After 1	nailing of a final Office Action or Notice of Allowance, but before payment of the
	issue f	ee.
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the
		amount of is enclosed.
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal
		form (PTO/SB/17 is attached to this submission in duplicate.)

Applicant would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petition and/or other

pa-1168987 2

Application Serial No. 10/661,165

Patent

Docket No. 543312000420

fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 543312000420.

Dated: May 30, 2007

Respectfully submitted,

Alicia J. Hager

Registration No.: 44,140

MORRISON & FOERSTER LLP

755 Page Mill Road

Palo Alto, California 94304-1018

(650) 813-4296



1

Sheet

ALTERNATIVE TO PTO/SB/08a/b (07-05)

Complete if Known

543312000420

TRACES.	Application Number	10/661,165
INFORMATION DISCLOSURE	Filing Date	September 11, 2003
STATEMENT BY APPLICANT	First Named Inventor	Ravinder S. DHALLAN
	Art Unit	1634
(Use as many sheets as necessary)	Examiner Name	E. Whisenant

Attorney Docket Number

3

			U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US-5,985,260-A	11-16-1999	Shanbrom	
	2.	US-6,033,861-A		Schafer et al.	
	3.	US-6,117,679-A	09-12-2000	Stemmer	
	4.	US-6,132,970-A		Stemmer	
	5.	US-6,153,410-A	11-28-2000		
	6.	US-6,165,793-A	12-26-2000		
-	7.	US-6,177,263-B1	 	Arnold et al.	
	8.	US-6,180,406-B1	01-30-2001	Stemmer	
	9.	US-6,183,958-B1	02-06-2001	Stanton, Jr.	
	10.	US-6,269,957-B1	08-07-2001	Bowers et al.	
	11.	US-6,277,638-B1	08-21-2001	Stemmer	
	12.	US-6,280,949-B1	08-28-2001	Lizardi	
	13.	US-6,287,861-B1	09-11-2001	Stemmer et al.	
	14.	US-6,291,242-B1	09-18-2001	Stemmer	
	15.	US-6,297,053-B1	10-02-2001	Stemmer	
	16.	US-6,323,009-B1		Lasken et al.	
	17.	US-6,323,030-B1	11-27-2001	Stemmer	
	18.	US-6,344,356-B1	02-05-2002		
•	19.	US-6,357,601-B1		Bowers et al.	
	20.	US-6,365,375-B1	04-02-2002	Dietmaier et al.	
	21.	US-6,372,497-B1	04-16-2002	Stemmer	
	22.	US-6,379,896-B1	04-30-2002	Stanton, Jr.	
	23.	US-6,395,547-B1	05-28-2002	Stemmer	
	24.	US-6,413,774-B1	07-02-2002		
	25.	US-6,440,706-B1		Vogelstein et al.	
	26.	US-6,444,468-B1		Stemmer et al.	
	27.	US-6,506,602-B1	01-14-2003	Stemmer	
	28.	US-6,518,065-B1	02-11-2003	1	
	29.	US-6,537,746-B2	03-25-2003		
	30.	US-6,573,098-B1	06-03-2003		
	31.	US-6,573,300-B2	06-03-2003	Chang et al.	
	32.	US-6,582,906-B1	06-24-2003	Cao et al.	
	33.	US-6,602,986-B1	08-05-2003		
	34.	US-6,617,137-B2	09-09-2003		
	35.	US-6,638,722-B2	10-28-2003		
	36.	US-6,642,034-B2	11-04-2003	Lizardi	
	37.	US-6,673,541-B1	01-06-2004		
	38.	US-6,673,551-B2	01-06-2004		
	39.	US-6,703,228-B1		Landers et al.	
	40.	US-6,780,593-B1	08-24-2004	Galibert et al.	
	41.	US-6,977,162-B2	12-20-2005	Dhallan	

Examiner	Date	
Signature	Considered	

Cuba	stitute for form 1449/PTO			Complete if Known		
Subs	stitute 101 101111 1449/P10			Application Number	10/661,165	
IN	FORMATION	N DI	SCLOSURE	Filing Date	September 11, 2003	
STATEMENT BY APPLICANT				First Named Inventor	Ravinder S. DHALLAN	
	.,	- . ,	AI I LIOAIII	Art Unit	1634	
(Use as many sheets as necessary)			necessary)	Examiner Name	E. Whisenant	
Sheet	2	of	3	Attorney Docket Number	543312000420	

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵		
	42.	WO-02/055985-A2, A3	07-18-2002	Roche Diagnostics Corporation				
	43.	WO-03/001181-A2, A3	01-03-2003	Quest Diagnostics Incorporated				

^{*}EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	44.	Anker, P. et al. (April 1997). "K-ras Mutations are Found in DNA Extracted from the Plasma of Patients with Colorectal Cancer," <i>Gastroenterology</i> 112(4):1114-1120.	
	45.	Cheung, V.G. et al. (December 1996). "Whole Genome Amplification Using a Degenerate Oligonucleotide Primer Allows Hundreds of Genotypes to be Performed on Less Than One Nanogram of Genomic DNA," PNAS 93:14676-14679.	
	46.	Dean, F.B. et al. (April 16, 2002). "Comprehensive Human Genome Amplification Using Multiple Displacement Amplification," <i>PNAS</i> 99(8):5261-5266.	
	47.	Dhallan, R. et al. (Published online February 2, 2007 and published in journal February 10, 2007). "A Non-Invasive Test for Prenatal Diagnosis Based on Fetal DNA Present in Maternal Blood: A Preliminary Study," <i>The Lancet</i> 369(9560):474-481.	
	48.	Fan, S. et al. (August 12, 1998). "Down-Regulation of BRCA1 and BRCA2 in Human Ovarian Cancer Cells Exposed to Adriamycin and Ultraviolet Radiation," <i>International Journal of Cancer</i> 77(4):600-609.	ı
	49.	Fortina, P. et al. (2001). "DOP-PCR Amplification of Whole Genomic DNA and Microchip-Based Capillary Electrophoresis," <i>Methods Mol. Biol.</i> 163:211-219.	
	50.	Gadkar, V. et al. (January 1, 2005). "Application of Phi29 DNA Polymerase Mediated Whole Genome Amplification on Single Spores of Arbuscular Mycorrhizal (AM) Fungi," FEMS Microbiology Letters 242(1):65-71.	
	51.	Gusev, Y. et al. (July 2001). "Technical Advance: Rolling Circle Amplification - A New Approach to Increase Sensitivity for Immunohistochemistry and Flow Cytometry," <i>American Journal of Pathology</i> 159(1):63-69.	
	52.	Hielm, S. et al. (February 1998). "Genomic Analysis of Clostridium Botulinum Group II by Pulsed-Field Gel Electrophoresis," Applied and Environmental Microbiology 64(2):703-708.	
	53.	Hosono, S. et al. (April 14, 2003). "Unbiased Whole-Genome Amplification Directly From Clinical Samples," <i>Genome Research</i> 13(5)954-964.	
	54.	Hughes, G.R. et al. (March-April 1971). "The Release of DNA into Serum and Synovial Fluid," <i>Arthritis and Rheumatology</i> 14(2):259-266.	
	55.	Imamura, A. et al. (1996). "Short Communication: Prenatal Diagnosis of Adrenoleukodystrophy by Means of Mutation Analysis," <i>Prenatal Diagnosis</i> 16:259-261.	

Examiner	Date	
Signature	 Considered	

Sub	ostitute for form 1449/PT0	^		Complete if Known		
Suc	osimule for form 1449/PTC	J		Application Number	10/661,165	
l in	NFORMATIC	N DIS	CLOSURE	Filing Date	September 11, 2003	
I	TATEMENT			First Named Inventor	Ravinder S. DHALLAN	
		DI A	LIOAIT	Art Unit	1634	
	(Use as many	sheets as n	ecessary)	Examiner Name	E. Whisenant	
Sheet	3	of	3	Attorney Docket Number	543312000420	

56.	Kösel, S. et al. (May 8, 2001). "Inter-Laboratory Comparison of DNA Preservation in Archival Paraffin-Embedded Human Brain Tissue from Participating Centres on Four Continents," <i>Neurogenetics</i> 3(3):163-170.
57.	Kusaka, T. et al. (October 2000). "Analysis of K-ras Codon 12 Mutations and p53 Overexpression in Colorectal Nodule-Aggregating Tumors," <i>Journal of Gastroenterology and Hepatology</i> 15(10):1151-1157.
58.	Leon, S.A. et al. (March 1977). "Free DNA in the Serum of Cancer Patients and the Effect of Therapy," Cancer Research 37:646-650.
59.	Maiwald, M. et al. (May 1995). "Evaluation of the Detection of <i>Borrelia Burgdorferi</i> DNA in Urine Samples by Polymerase Reaction," <i>Infection</i> 23(3):173-179.
60.	Moreton, J.A. et al. (1999). "Use of Virkon as a Disinfectant for Clinical Samples Carrying a High Risk of Infection in Inductively Coupled Plasma Mass Spectrometry," <i>Journal of Analytical Atomic Spectrometry</i> 14:893-894.
61.	National Kidney and Urologic Diseases Information Clearinghouse. (December 2005). "Urinary Tract Infections in Adults," NIH Publication No. 06-2097, located at http://kidney.niddk.nih.gov/kudiseases/pubs/utiadult , last visited on April 26, 2007, nine pages.
62.	Reaney, P. (February 1, 2007). "New Down's Test Eliminates Miscarriage Risk," located at http://www.reuters.com , one page.
63.	Siva, S.C. et al. (February 3, 2003). "Evaluation of the Clinical Usefulness of Isolation of Fetal DNA from the Maternal Circulation," <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> 43(1):10-15.
64.	Smirnov, D.A. et al. (May 2004). "Method for Manufacturing Whole-Genome Microarrays by Rolling Circle Amplification," <i>Genes, Chromosomes, & Cancer</i> 40(1):72-77.
65.	Supplementary European Search Report mailed on January 10, 2007 for EP Application No. 03 74 9291.5, five pages.
66.	Supplementary European Search Report mailed on January 22, 2007 for EP Application No. 04 71 6171.6, five pages.
67.	Supplementary European Search Report mailed on July 4, 2006 for EP Application No. 03 74 3737.3, three pages.
68.	The Internet Pathology Laboratory. (Date Unknown). "Human Immunodeficiency Virus (HIV)," located at http://library.med.utah.edu/WebPath/TUTORIAL/AIDS/HIV.html , last visited on April 11, 2007, seven pages.
69.	Unrau, P. et al. (August 5, 1994) "Non-Cloning Amplification of Specific DNA Fragments from Whole Genomic DNA Digests Using DNA 'Indexers'," <i>Gene</i> 145(1):163-169.
70.	Wang, G. et al. (May 21, 2004). "Balanced-PCR Amplification Allows Unbiased Identification of Genomic Copy Changes in Minute Cell and Tissue Samples," <i>Nucleic Acids Research</i> 32(9): e76, 10 pages.
71.	Wells, D. et al. (1999). "Detailed Chromosomal and Molecular Genetic Analysis of Single Cells by Whole Genome Amplification and Comparative Genomic Hybridisation," <i>Nucelic Acids Res.</i> 27(4):1214-1218.
72.	Zheng, S. et al (June 2001). "Whole Genome Amplification Increases the Efficiency and Validity of Buccal Cell Genotyping in Pediatric Populations," Cancer Epidemiology, Biomarkers, & Prevention 10:697-700.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	3

Complete if Known					
Application Number	10/661,165				
Filing Date	September 11, 2003				
First Named Inventor	Ravinder S. DHALLAN				
Art Unit	1634				
Examiner Name	E. Whisenant				
Attorney Docket Number	543312000420				

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	1.	US-5,985,260-A	11-16-1999	Shanbrom			
	2.	US-6,033,861-A	03-07-2000	Schafer et al.			
	3.	US-6,117,679-A	09-12-2000	Stemmer			
	4.	US-6,132,970-A	10-17-2000	Stemmer			
	5.	US-6,153,410-A	11-28-2000	Arnold et al.			
	6.	US-6,165,793-A	12-26-2000	Stemmer			
	7.	US-6,177,263-B1	01-23-2001	Arnold et al.			
	8.	US-6,180,406-B1	01-30-2001	Stemmer			
	9.	US-6,183,958-B1	02-06-2001	Stanton, Jr.			
	10.	US-6,269,957-B1	08-07-2001	Bowers et al.			
***	11.	US-6,277,638-B1	08-21-2001	Stemmer			
	12.	US-6,280,949-B1		Lizardi			
	13.	US-6,287,861-B1		Stemmer et al.			
	14.	US-6,291,242-B1	09-18-2001	Stemmer	·		
	15.	US-6,297,053-B1	10-02-2001	Stemmer			
	16.	US-6,323,009-B1	11-27-2001	Lasken et al.			
	17.	US-6,323,030-B1	11-27-2001	Stemmer			
	18.	US-6,344,356-B1	02-05-2002	Stemmer			
	19.	US-6,357,601-B1	03-19-2002	Bowers et al.			
	20.	US-6,365,375-B1	04-02-2002	Dietmaier et al.			
	21.	US-6,372,497-B1	04-16-2002	Stemmer			
	22.	US-6,379,896-B1	04-30-2002	Stanton, Jr.			
	23.	US-6,395,547-B1	05-28-2002	Stemmer			
	24.	US-6,413,774-B1	07-02-2002	Stemmer et al.			
	25.	US-6,440,706-B1	08-27-2002	Vogelstein et al.			
	26.	US-6,444,468-B1	09-03-2002	Stemmer et al.			
	27.	US-6,506,602-B1	01-14-2003	Stemmer			
	28.	US-6,518,065-B1	02-11-2003	Stemmer			
	29.	US-6,537,746-B2	03-25-2003	Arnold et al.			
	30.	US-6,573,098-B1	06-03-2003	Stemmer			
	31.	US-6,573,300-B2	06-03-2003	Chang et al.			
	32.	US-6,582,906-B1	06-24-2003	Cao et al.			
	33.	US-6,602,986-B1	08-05-2003	Stemmer et al.			
	34.	US-6,617,137-B2	09-09-2003	Dean et al.			
	35.	US-6,638,722-B2	10-28-2003	Ji et al.			
	36.	US-6,642,034-B2	11-04-2003				
	37.	US-6,673,541-B1	01-06-2004	Klein et al.			
	38.	US-6,673,551-B2	01-06-2004	Stanton, Jr.			
	39.	US-6,703,228-B1		Landers et al.			
	40.	US-6,780,593-B1	08-24-2004				
	41.	US-6,977,162-B2	12-20-2005	Dhallan			

Examiner	 Date	
Signature	 Considered	

Substitute for form 1449/PTO			·	Complete if Known		
Suc	ostitute for form 1449/PTO			Application Number 10/661,165		
l in	NFORMATION	l Di	SCLOSURE	Filing Date	September 11, 2003	
STATEMENT BY APPLICANT				First Named Inventor	Ravinder S. DHALLAN	
	OTATEMENT DI ALL LIOANT			Art Unit	1634	
(Use as many sheets as necessary)			s necessary)	Examiner Name	E. Whisenant	
Sheet	2	of	3	Attorney Docket Number	543312000420	

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures	T ⁶		
,	42.	WO-02/055985-A2, A3		Roche Diagnostics Corporation	Appear	-		
	43.	WO-03/001181-A2, A3	01-03-2003	Quest Diagnostics Incorporated				

^{*}EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS			
Examiner Cite No.1					
	44.	Anker, P. et al. (April 1997). "K-ras Mutations are Found in DNA Extracted from the Plasma of Patients with Colorectal Cancer," <i>Gastroenterology</i> 112(4):1114-1120.			
	45.	Cheung, V.G. et al. (December 1996). "Whole Genome Amplification Using a Degenerate Oligonucleotide Primer Allows Hundreds of Genotypes to be Performed on Less Than One Nanogram of Genomic DNA," PNAS 93:14676-14679.			
	46.	Dean, F.B. et al. (April 16, 2002). "Comprehensive Human Genome Amplification Using Multiple Displacement Amplification," <i>PNAS</i> 99(8):5261-5266.			
1	47.	Dhallan, R. et al. (Published online February 2, 2007 and published in journal February 10, 2007). "A Non-Invasive Test for Prenatal Diagnosis Based on Fetal DNA Present in Maternal Blood: A Preliminary Study," <i>The Lancet</i> 369(9560):474-481.	i		
	48.	Fan, S. et al. (August 12, 1998). "Down-Regulation of BRCA1 and BRCA2 in Human Ovarian Cancer Cells Exposed to Adriamycin and Ultraviolet Radiation," <i>International Journal of Cancer</i> 77(4):600-609.			
	49.	Fortina, P. et al. (2001). "DOP-PCR Amplification of Whole Genomic DNA and Microchip-Based Capillary Electrophoresis," <i>Methods Mol. Biol.</i> 163:211-219.			
	50.	Gadkar, V. et al. (January 1, 2005). "Application of Phi29 DNA Polymerase Mediated Whole Genome Amplification on Single Spores of Arbuscular Mycorrhizal (AM) Fungi," FEMS Microbiology Letters 242(1):65-71.			
	51.	Gusev, Y. et al. (July 2001). "Technical Advance: Rolling Circle Amplification - A New Approach to Increase Sensitivity for Immunohistochemistry and Flow Cytometry," <i>American Journal of Pathology</i> 159(1):63-69.			
	52.	Hielm, S. et al. (February 1998). "Genomic Analysis of Clostridium Botulinum Group II by Pulsed-Field Gel Electrophoresis," Applied and Environmental Microbiology 64(2):703-708.			
	53.	Hosono, S. et al. (April 14, 2003). "Unbiased Whole-Genome Amplification Directly From Clinical Samples," Genome Research 13(5)954-964.			
	54.	Hughes, G.R. et al. (March-April 1971). "The Release of DNA into Serum and Synovial Fluid," Arthritis and Rheumatology 14(2):259-266.			
	55.	Imamura, A. et al. (1996). "Short Communication: Prenatal Diagnosis of Adrenoleukodystrophy by Means of Mutation Analysis," <i>Prenatal Diagnosis</i> 16:259-261.			

Examiner		Date	
Signature		Considered	

Cub				Complete if Known		
Suc	ostitute for form 1449/PTO			Application Number	10/661,165	
l in	NFORMATIO	N DIS	SCLOSURE	Filing Date	September 11, 2003	
	STATEMENT BY APPLICANT			First Named Inventor	Ravinder S. DHALLAN	
"	'IAI LINLIN	<i>D</i> 1 <i>A</i>	II LIOAIII	Art Unit	1634	
(Use as many sheets as necessary)			necessary)	Examiner Name	E. Whisenant	
Sheet	3	of	3	Attorney Docket Number	543312000420	

56.	Kösel, S. et al. (May 8, 2001). "Inter-Laboratory Comparison of DNA Preservation in Archival Paraffin-Embedded Human Brain Tissue from Participating Centres on Four Continents," Neurogenetics 3(3):163-170.
57.	Kusaka, T. et al. (October 2000). "Analysis of K-ras Codon 12 Mutations and p53 Overexpression in Colorectal Nodule-Aggregating Tumors," <i>Journal of Gastroenterology and Hepatology</i> 15(10):1151-1157.
58.	Leon, S.A. et al. (March 1977). "Free DNA in the Serum of Cancer Patients and the Effect of Therapy," Cancer Research 37:646-650.
59.	Maiwald, M. et al. (May 1995). "Evaluation of the Detection of <i>Borrelia Burgdorferi</i> DNA in Urine Samples by Polymerase Reaction," <i>Infection</i> 23(3):173-179.
60.	Moreton, J.A. et al. (1999). "Use of Virkon as a Disinfectant for Clinical Samples Carrying a High Risk of Infection in Inductively Coupled Plasma Mass Spectrometry," <i>Journal of Analytical Atomic Spectrometry</i> 14:893-894.
61.	National Kidney and Urologic Diseases Information Clearinghouse. (December 2005). "Urinary Tract Infections in Adults," NIH Publication No. 06-2097, located at http://kidney.niddk.nih.gov/kudiseases/pubs/utiadult , last visited on April 26, 2007, nine pages.
62.	Reaney, P. (February 1, 2007). "New Down's Test Eliminates Miscarriage Risk," located at http://www.reuters.com , one page.
63.	Siva, S.C. et al. (February 3, 2003). "Evaluation of the Clinical Usefulness of Isolation of Fetal DNA from the Maternal Circulation," <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> 43(1):10-15.
64.	Smirnov, D.A. et al. (May 2004). "Method for Manufacturing Whole-Genome Microarrays by Rolling Circle Amplification," Genes, Chromosomes, & Cancer 40(1):72-77.
65.	Supplementary European Search Report mailed on January 10, 2007 for EP Application No. 03 74 9291.5, five pages.
66.	Supplementary European Search Report mailed on January 22, 2007 for EP Application No. 04 71 6171.6, five pages.
67.	Supplementary European Search Report mailed on July 4, 2006 for EP Application No. 03 74 3737.3, three pages.
68.	The Internet Pathology Laboratory. (Date Unknown). "Human Immunodeficiency Virus (HIV)," located at http://library.med.utah.edu/WebPath/TUTORIAL/AIDS/HIV.html , last visited on April 11, 2007, seven pages.
69.	Unrau, P. et al. (August 5, 1994) "Non-Cloning Amplification of Specific DNA Fragments from Whole Genomic DNA Digests Using DNA 'Indexers'," <i>Gene</i> 145(1):163-169.
70.	Wang, G. et al. (May 21, 2004). "Balanced-PCR Amplification Allows Unbiased Identification of Genomic Copy Changes in Minute Cell and Tissue Samples," <i>Nucleic Acids Research</i> 32(9): e76, 10 pages.
71.	Wells, D. et al. (1999). "Detailed Chromosomal and Molecular Genetic Analysis of Single Cells by Whole Genome Amplification and Comparative Genomic Hybridisation," <i>Nucelic Acids Res.</i> 27(4):1214-1218.
72.	Zheng, S. et al (June 2001). "Whole Genome Amplification Increases the Efficiency and Validity of Buccal Cell Genotyping in Pediatric Populations," <i>Cancer Epidemiology</i> , <i>Biomarkers</i> , & <i>Prevention</i> 10:697-700.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	 Considered	

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.